Photofrin (porfimer sodium)

P2, N=52, Active, not recruiting, Abramson Cancer Center at Penn Medicine | Recruiting --> Active, not recruiting | N=102 --> 52

P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Trial primary completion date: Nov 2023 --> Jul 2024

P1, N=5, Terminated, Roswell Park Cancer Institute | Active, not recruiting --> Terminated; Low accrual

P1, N=5, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=12 --> 5

P1, N=5, Active, not recruiting, Roswell Park Cancer Institute | Suspended --> Active, not recruiting | N=16 --> 5 | Trial completion date: Mar 2025 --> Jan 2026 | Trial primary completion date: Mar 2025 --> Feb 2024

P2, N=102, Recruiting, Abramson Cancer Center at Penn Medicine | Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: May 2024 --> Dec 2024

P1/2, N=19, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=65 --> 19 | Trial primary completion date: Feb 2030 --> Nov 2023

This study reveals changes in the expression level of some genes associated with cisplatin-resistant ovarian cancer. In addition, a new small molecule compound was identified for the treatment of cisplatin-resistant ovarian cancer.

P1, N=16, Suspended, Roswell Park Cancer Institute | Recruiting --> Suspended

P1, N=12, Recruiting, Roswell Park Cancer Institute | Phase classification: P2 --> P1 | N=82 --> 12

P2, N=82, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

P1, N=9, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Mar 2025 --> Nov 2025 | Trial primary completion date: Mar 2025 --> Nov 2023

In lung cancer, porfimer sodium, chlorin e6, and verteporfin have shown promising results in preclinical studies and clinical trials...PDT with temoporfin, redaporfin, photochlor, and IR700 shows potential in early stage larynx cancer and recurrent head and neck carcinoma...In conclusion, PDT continues to evolve as a promising cancer treatment strategy, with ongoing research spanning from fundamental investigations to clinical trials, exploring various photosensitizers and treatment combinations. This review sheds light on the recent advancements in PDT for cancer therapy and highlights its potential for personalized and targeted treatments.

The most commonly used photosensitizers include 5-aminolevulinic acid for the enzymatic generation of protoporphyrin IX, Temoporfin-THPC, Photofrin, Hypericin and Talaporfin. An overview of all three generations of photosensitizers is presented. Along with an indication of the limitations of the treatment of brain tumors, intraoperative photodynamic therapy and its possibilities are described as an alternative therapeutic method.

In this bedside-to-bench study, Photofrin-based PDT introduced the possibility of achieving a long-term response in murine models of MPM tumors that were surgically debulked by 60% to 90%...Although mesothelioma is difficult to treat, we have shown that combining surgery with a form of radiation, photodynamic therapy, may help people with mesothelioma live longer. In this study, we demonstrate in mice that this regimen could be further improved by addressing the inflammation induced as a by-product of surgery.

To overcome these problems, photodynamic therapy (PDT) has previously been investigated using Photofrin as a photosensitizer (PS)...Therefore, the reactive oxygen species (ROS) produced by SDT and PDT follow two distinct pathways, i.e., type I (oxygen independent) and type II (oxygen dependent), respectively, and results in significantly enhanced destruction of tumor cells. The preliminary in vitro and in vivo results in a PC3 cell line and tumor model indicate that the tumor specificality of the therapeutic agent(s) can be increased by targeting galectin-1 and galectin-3, known for their overexpression in prostate cancer.

P1/2, N=65, Recruiting, Roswell Park Cancer Institute | N=36 --> 65 | Trial completion date: Feb 2024 --> Feb 2030 | Trial primary completion date: Feb 2024 --> Feb 2030

PEDSy-MC is accompanied by a dose-cavity visualization tool that allows real-time inspection of dose values of the treated cavity in 2D and 3D, which will be expanded to ongoing clinical trials at PSM. PSM has developed a technology to measure 8-detectors in a pleural cavity phantom using Photofrin-mediated PDT that has been used during validation.

The major three docking software packages were used to analyze the scoring/H-bonding energy and intermolecular interactions. Based on the results, we concluded that FOXO6 was upregulated in gastric cancer and the ligand porfimer sodium emerges as a promising potential FOXO6 inhibitor to curtail gastric cancer progression.

P1, N=16, Recruiting, Roswell Park Cancer Institute | Trial completion date: Sep 2023 --> Mar 2025 | Trial primary completion date: Sep 2023 --> Mar 2025

Knowledge of the mechanisms of resistance to photodamage in Ras-overexpressing cells may lead to the optimization of the combination of PDT with other treatments.

P1, N=16, Recruiting, Roswell Park Cancer Institute | Trial completion date: Dec 2023 --> Sep 2023 | Trial primary completion date: Dec 2022 --> Sep 2023

To understand the impact of photodynamic interventions on cerebrovascular endothelial cells, we evaluated the dosage-dependent impact of porfimer sodium-mediated PDT on B.END3 cells using flow cytometer, comet assay, RNA sequencing, and bioinformatics analysis...To further perform qRT-PCR assays, we find that TNF-α/NF-κB and KRAS pathways were substantially up-regulated, consistent with GSEA analysis. The current findings suggested that a low dosage of PDT intervention may be detrimental to the homeostasis of blood-brain barrier (BBB) by inducing the inflammatory response and affecting the expression of surface biomarkers.

P1, N=16, Recruiting, Roswell Park Cancer Institute | Not yet recruiting --> Recruiting

P1, N=16, Not yet recruiting, Roswell Park Cancer Institute

Mini-LED based i-PDT also induced caspase-3-like activation following downregulation of Bcl-2 and upregulation of Bax protein levels in tumors, while it reduced cell proliferation and expression of VEGF.ConclusionsThe mini-LED based i-PDT with photofrin exhibited promising antitumor effects possibly via inducing apoptotic cell death in the pre-clinical xenograft study of pancreatic cancer, which appeared to be more potent than conventional i-PDTs. Our data provide preliminary evidence on the great promise of mini-LED based i-PDT in patients with pancreatic cancer.